Story excerpt provided by Crain’s Cleveland Business.
Written by Scott Suttell.
Cleveland biotechnology company Athersys Inc. (Nasdaq: ATHX) announced that Healios K.K., its partner in Japan, has enrolled the first patient in a study evaluating MultiStem cell therapy treatment of patients who have suffered an ischemic stroke.
Athersys said in a Nov. 15 news release that the Healios study, known as TREASURE., is designed to enroll a total of 220 patients with moderate to severe strokes.
Click here to read the complete article.
Originally published November 16, 2017.